These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2168262)

  • 1. [Clinical evaluation of fosfomycin].
    Lan CK
    Zhonghua Yi Xue Za Zhi (Taipei); 1990 Mar; 45(3):181-5. PubMed ID: 2168262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of fosfomycin in the treatment of bacterial infections.
    Hutzler R; Fernandes V; Muñoz D; Rozentraub A
    Chemotherapy; 1977; 23 Suppl 1():358-64. PubMed ID: 832537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriological evaluation of fosfomycin in clinical studies.
    Rodríguez A; Gallego A; Olay T; Mata JM
    Chemotherapy; 1977; 23 Suppl 1():247-58. PubMed ID: 832523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosfomycin in chronic urinary infections.
    Allona A; Díaz Cabrera JA; Manchado P
    Chemotherapy; 1977; 23 Suppl 1():267-74. PubMed ID: 851501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
    Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
    J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosfomycin in the treatment of bacterial infections: summary of clinical trials in Japan.
    Fujii R
    Chemotherapy; 1977; 23 Suppl 1():234-46. PubMed ID: 832522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fosfomycin in the treatment of some infectious diseases].
    Aceti A; Vullo V; Ferone U; Delia S
    Clin Ter; 1979 Jan; 88(1):61-6. PubMed ID: 436378
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trials with cefoperazone in the field of internal medicine in Japan.
    Mashimo K; Kunii O
    Clin Ther; 1980; 3(Spec Issue):159-72. PubMed ID: 6446392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical chemotherapeutic evaluation of fosfomycin plus amoxicillin (co-fosfolactamine): a prospective double-blind clinical trial.
    Novelli A; Rizzo M; Buzzoni P; Coronnello M; Alunno Pergentini S; Giganti E; Periti P
    Chemioterapia; 1984 Oct; 3(5):281-5. PubMed ID: 6398125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosfomycin in the treatment of gynecological infections.
    Gobernado M; Pérez de León A; Santos M; Mateo C; Ferreres L
    Chemotherapy; 1977; 23 Suppl 1():287-92. PubMed ID: 832527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin in treatment of respiratory bacterial infections.
    Bonora V; Lozano C; Santos M; Paz M; Baguena J; Gobernado M
    Chemotherapy; 1977; 23 Suppl 1():337-41. PubMed ID: 832534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosfomycin. Controlled clinical studies.
    Rodriguez A; Olay T; Vicente MV; Oliver LE
    G Ital Chemioter; 1977; 23(2):127-32. PubMed ID: 342325
    [No Abstract]   [Full Text] [Related]  

  • 16. Temocillin treatment of serious infections due to gram-negative bacilli in an intensive care unit.
    Offenstadt G; Lesage D; Hericord P; Pinta P; Leaute JB; Amstutz P
    Drugs; 1985; 29 Suppl 5():213-20. PubMed ID: 3896741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of ceftriaxone in severe infections in adults].
    Lacut JY; Dupon M; Quentin C; Brachet-Liermain A; Granger C; Echinard E
    Pathol Biol (Paris); 1986 May; 34(5):451-6. PubMed ID: 3534720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical experience with fosfomycin in urinary tract infections (author's transl)].
    Peters HJ; Eicher R
    MMW Munch Med Wochenschr; 1981 May; 123(18):748-50. PubMed ID: 6785627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of the combination of carumonam and fosfomycin in the treatment of complicated urinary tract infection].
    Kakizaki H; Ishii N; Murakami S; Suzuki K; Takamizawa A; Hirano J; Mitobe K; Saito M; Hirano K; Imamura A
    Hinyokika Kiyo; 1990 Jun; 36(6):731-5. PubMed ID: 2239570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.